Table 1.
Baseline demographics
| Determinant | Anterior tumour | Posterior tumour | p value | ||
|---|---|---|---|---|---|
| Median/mean/N | IQR/% | Median/mean/N | IQR/% | ||
| Age at treatment (in years), median, (IQR) | 64 | 59–68 | 66 | 60–71 | 0.531 |
| ADT pre treatment, N, (%) | 5 | 11% | 24 | 11% | 0.970 |
| PSA pre treatment (in ng/ml), median, (IQR) | 7.53 | 5.22–10.77 | 6.92 | 5.05–9.64 | 0.496 |
| Prostate volume (MRI, in ml), mean, (range) | 33 | 28–40 | 36 | 28–47 | 0.315 |
| Biopsy results pre treatment, median, (IQR) | |||||
| No. positive cores | 7 | 3–13 | 5 | 4–9 | 0.009 |
| MCCL (in mm) | 6.5 | 5–8.75 | 6 | 4–8 | 0.597 |
| Max. cancer percentage of core (%) | 50 | 40–76 | 60 | 39–75 | 0.507 |
| Gleason score pre treatment, median | 3 + 4 | 3 + 4 | |||
| 3 + 4 | 38 | 84% | 181 | 82% | 0.832 |
| 4 + 3 | 7 | 16% | 36 | 16% | 1.000 |
| 4 + 4 | 0 | 0% | 5 | 2% | 0.593 |
| T-stage pre treatment, median, N, (%) | T2 | T2 | |||
| T1c | 5 | 11% | 10 | 4% | 0.145 |
| T2a | 3 | 7% | 15 | 7% | 1.000 |
| T2b | 27 | 60% | 117 | 53% | 0.415 |
| T2c | 6 | 13% | 50 | 22% | 0.228 |
| T3a | 4 | 9% | 28 | 13% | 0.619 |
| T3b | 0 | 0% | 2 | 1% | 1.000 |
N number, IQR inter quartile range, ADT androgen deprivation therapy, MRI magnetic resonance imaging, ml millilitres, MCCL maximum cancer core length, cm centimetre